A new peer-reviewed study concluded that the mortality rate in people who used ivermectin regularly was 92 percent lower than in non-users and 84 percent lower than in irregular users.
Among the authors are Flávio Cadegiani, a board-certified endocrinologist, and Pierre Kory, an outspoken pulmonary and critical care medicine specialist, as well as president and chief medical officer of the Front Line Critical Care Alliance.
The study, published on Aug. 31 in the Cuerus Journal of Medical Science, was conducted via a prospective observational study of a “strictly controlled population” of 88,012 subjects in the Brazilian city of Itajaí.
The individuals that took ivermectin as a preventive medicine prior to COVID infection saw remarkable reductions in hospitalization as well as death, according to the publication.
The citywide program ran through July 7 and Dec. 2 of 2020, and was collected prospectively and systematically.
The method involved giving a smaller dose of ivermectin (proportional to body weight) for 150 days to a group considered the “irregular” group and up to three times or more of that dosage to the “regular” group.
“Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates,” the study states.
In addition, the study asserts that the hospitalization rate was reduced by 100 percent in the “regular” group.
McCullough and Zelenko Protocols
Dr. Benjamin Marble, an urgent care specialist in Florida who has been practicing for over two decades, asserts that he and his group have treated about 150,000 acute COVID-19 patients and have only lost 6 people.
The nearly 100 percent effectiveness was achieved, Marble says, using the “McCullough protocol” (pdf) of which ivermectin is the cornerstone drug.
“This is another great study which proves ivermectin works against COVID-19, something I already knew is a simple fact,” Marble told The Epoch Times.
Marble thinks that this study “should be the nail in the coffin” to the claims that ivermectin does not help against COVID.
Kevin Jenkins, the co-chair of the Zelenko Foundation said: “This study proves what we have known for some time, that ivermectin was an effective tool to combat COVID-19.”
“Sadly, the only thing that comes to my mind is the lives that we’ve lost,” Jenkins told The Epoch Times.
The “Zelenko Protocol” is a combination of hydroxychloroquine, ivermectin, zinc, azithromycin, and other drugs, including steroids.
‘Legacy Media Has Lost All of What’s Left of Their Credibility’
“You are not a horse. You are not a cow. Seriously, y’all. Stop it,” the FDA wrote on Twitter on Aug. 21, 2021.
Jenkins is of the opinion that the organizations that suppressed the use of these drugs should “be brought to justice.”
“Legacy media has lost all of what’s left of their credibility! These agencies pushed the greatest misinformation campaign known to man!” Jenkins said, “[they’re] going to pay.”
Jenkins, along with Robert F. Kennedy Jr. and Dr. Christiane Northrup, who were been dubbed as part of the “Disinformation Dozen,” recently spoke to The Epoch Times after documents showed the Biden administration engaged in widespread censorship efforts that directly affected them.
At least two groups, the Front Line COVID-19 Critical Care Alliance and the British Ivermectin Recommendation Development Group, have been advocating for the off-label use of ivermectin to treat COVID-19 in its early stages.
The CDC said in an Aug. 26, 2021 health advisory (pdf) that ivermectin hasn’t been approved or authorized by the FDA “for the prevention or treatment of COVID-19 and the National Institutes of Health (NIH) has also determined that there are currently insufficient data to recommend ivermectin for the treatment of COVID-19.”
The American Medical Association, the American Pharmacists Association, and the American Society of Health-System Pharmacists said in a joint statement in September 2021 that they were against its use to treat COVID-19 outside of a clinical trial.
Mimi Nguyen Ly contributed to this report.